November 23, 2016 - By whatsonthorold
At an average price-per-share of $13.7, Craig Wheeler, the Momenta Pharmaceuticals Inc’s President sold 5,880 shares of Momenta Pharmaceuticals Inc worth $80,433 US Dollars. Today, Craig Wheeler owns 533,690 shares which are exactly 0.77% of the Company’s total market capitalization. A report documented published 23-11-2016 with the Washington-based SEC, made public here, shows the full details of the transaction.
Out of 9 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 5 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 56% are positive. $31 is the highest target while $6 is the lowest. The $17.11 average target is 26.93% above today’s ($13.48) stock price. Momenta Pharmaceuticals has been the topic of 17 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm earned “Overweight” rating on Tuesday, October 11 by Barclays Capital. Leerink Swann maintained the stock with “Outperform” rating in Wednesday, May 4 report. Maxim Group upgraded Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) on Friday, January 8 to “Hold” rating. Aegis Capital initiated the shares of MNTA in a report on Tuesday, November 22 with “Hold” rating. The company was initiated on Friday, November 13 by JP Morgan. The firm has “Neutral” rating by Goldman Sachs given on Monday, June 6. On Monday, November 23 the stock rating was initiated by Barclays Capital with “Equal-Weight”. The firm has “Outperform” rating by Leerink Swann given on Tuesday, October 13. The rating was downgraded by Goldman Sachs on Thursday, August 6 to “Neutral”. The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has “Sell” rating given on Wednesday, September 7 by Maxim Group.
Insitutional Activity: The institutional sentiment decreased to 1.35 in Q2 2016. Its down 0.03, from 1.38 in 2016Q1. The ratio dived, as 23 funds sold all Momenta Pharmaceuticals, Inc. shares owned while 30 reduced positions. 15 funds bought stakes while 58 increased positions. They now own 57.30 million shares or 1.40% less from 58.11 million shares in 2016Q1.
Teacher Retirement Systems Of Texas, a Texas-based fund reported 8,996 shares. Savings Bank Of New York Mellon Corporation accumulated 0% or 706,600 shares. Deere reported 36,181 shares or 0.02% of all its holdings. The New York-based Tower Ltd Limited Liability Company (Trc) has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Envestnet Asset Management, a Illinois-based fund reported 22,815 shares. Turner Invs Lp reported 194,014 shares or 0.66% of all its holdings. Sabby Mngmt Limited Liability Corp holds 0.08% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 145,600 shares. The Louisiana-based Louisiana State Employees Retirement has invested 0.02% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Swiss Bankshares accumulated 113,700 shares or 0% of the stock. Primecap Mngmt Ca accumulated 2.74M shares or 0.03% of the stock. Moreover, Morgan Stanley has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 62,566 shares. Deutsche National Bank & Trust Ag has 248,009 shares for 0% of their US portfolio. Moreover, Teachers Retirement Systems Of The State Of Kentucky has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 15,700 shares. Sectoral Asset Mgmt last reported 0.64% of its portfolio in the stock. Moreover, Creative Planning has 0% invested in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 1,600 shares.
Insider Transactions: Since June 1, 2016, the stock had 0 buys, and 6 insider sales for $188,231 net activity. On Friday, August 19 the insider Roach James M. sold $13,151. Shares for $11,717 were sold by Shea Richard P on Friday, August 19. On Friday, August 19 the insider Kaundinya Ganesh Venkataraman sold $12,644. Leicher Bruce had sold 1,030 shares worth $12,415. 5,880 shares were sold by WHEELER CRAIG A, worth $70,704 on Friday, August 19. 5,200 shares were sold by Shapiro Bennett M, worth $67,600 on Wednesday, June 1.
About 180,812 shares traded hands. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 37.98% since April 21, 2016 and is uptrending. It has outperformed by 32.65% the S&P500.
Momenta Pharmaceuticals, Inc. is a biotechnology company. The company has a market cap of $892.77 million. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It currently has negative earnings. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics.
According to Zacks Investment Research, “Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.”
Analysts await Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to report earnings on February, 16. They expect $-0.21 EPS, up 51.16% or $0.22 from last year’s $-0.43 per share. After $-0.26 actual EPS reported by Momenta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -19.23% EPS growth.
More notable recent Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) news were published by: Fool.com which released: “Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales” on November 04, 2016, also Fool.com with their article: “Why Momenta Pharmaceuticals, Inc. Jumped Higher Today” published on October 11, 2016, Fool.com published: “Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February — Here’s Why” on March 04, 2016. More interesting news about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were released by: Fool.com and their article: “Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?” published on August 09, 2016 as well as Fool.com‘s news article titled: “Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today” with publication date: February 18, 2016.
Momenta Pharmaceuticals, Inc., incorporated on May 17, 2001, is a biotechnology company. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Firm focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Firm has developed generic version of Lovenox (enoxaparin sodium injection).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.